GlassScriptPhysician profile
Shea Smith Joyner
NPI 1114911310
$1,428.22
in general payments reported to CMS, 2019-2025
25 companies · $76.27 in 2025
The $76.27 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $174 · 2020: $83.77 · 2021: $379 · 2022: $397 · 2023: $160 · 2024: $158 · 2025: $76.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $394.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $314.13 | 2019-2023 | |
| Astellas Pharma US INC | $192.26 | 2022-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $162.18 | 2019-2023 | |
| Hologic Sales and Service, LLC | $138.45 | 2021-2025 | Aptima, Thinprep 2000 Processor, Novasure |
| Gynesonics, INC. | $97.45 | 2021 | |
| Aspira Women'S Health INC | $90.49 | 2022 | |
| Allergan, INC. | $67.67 | 2019-2020 | |
| Mylan Pharmaceuticals INC. | $45.81 | 2020-2022 | |
| Medtronic, INC. | $31.78 | 2022-2024 | Ligasure |
| Scynexis, INC. | $30.77 | 2022 | |
| Mission Pharmacal Company | $27.91 | 2019-2020 | |
| Organon LLC | $27.43 | 2021-2024 | |
| Daiichi Sankyo INC. | $25.50 | 2023 | Injectafer |
| Axonics, INC. | $23.34 | 2023 | Bulkamid |
| Abbott Laboratories | $20.65 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $18.54 | 2022 | |
| Duchesnay USA Incorporated | $18.23 | 2019 | |
| Minerva Surgical, INC | $16.46 | 2022 | |
| Sage Therapeutics, LLC | $15.90 | 2025 | Zurzuvae |
| Millicent US INC | $14.65 | 2024 | Femring, Intrarosa |
| Nalpropion Pharmaceuticals LLC | $13.77 | 2019 | |
| Therapeuticsmd, INC. | $13.50 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.25 | 2019 | |
| Channel Medsystems, INC. | $8.10 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shea Joyner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.